UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

European journal of cancer (1990), 2015-07, Vol.51 (11), p.1405-1414

2015

Volltextzugriff (PDF)

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

Annals of oncology, 2018-11, Vol.29 (11), p.2240-2246

2018

Volltextzugriff (PDF)

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer

Annals of oncology, 2019-09, Vol.30 (9), p.1472-1478

2019

Volltextzugriff (PDF)

Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity

Therapeutic Advances in Medical Oncology, 2010-09, Vol.2 (5), p.309-317

2010

Volltextzugriff (PDF)

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C

Annals of oncology, 2012-06, Vol.23 (6), p.1531-1536

2012

Volltextzugriff (PDF)

435P The AGITG Modulate study: Randomised phase II study testing manipulation of the tumour micro environment (TME) to enable synergy with PD1 inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

Annals of oncology, 2021-09, Vol.32, p.S552-S552

2021

Volltextzugriff (PDF)

1670P Circulating tumor DNA (ctDNA) dynamics of response and resistance in BRAF V600E mutant (mt) metastatic colorectal (mCRC) and other cancers: Data from EVICT (erlotinib and vemurafenib in combination trial)

Annals of oncology, 2022-09, Vol.33, p.S1307

2022

Volltextzugriff (PDF)

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

Annals of oncology, 2013-03, Vol.24 (3), p.710-718

2013

Volltextzugriff (PDF)

Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases

Gut, 2003-04, Vol.52 (4), p.568-573

2003

Volltextzugriff (PDF)

Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer

Annals of oncology, 2017-06, Vol.28 (suppl_3), p.iii135-iii136

2017

Volltextzugriff (PDF)

Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab

Annals of oncology, 2011-08, Vol.22 (8), p.1834-1838

2011

Volltextzugriff (PDF)

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17

Annals of oncology, 2013-04, Vol.24 (4), p.953-960

2013

Volltextzugriff (PDF)

Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer

Annals of oncology, 2017-06, Vol.28, p.iii167-iii167

2017

Volltextzugriff (PDF)

Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Therapy in Patients with Advanced Met-Positive Gastric or Gastroesophageal Junction (G/Gej) Adenocarcinoma

Annals of oncology, 2014-09, Vol.25, p.iv250

2014

Volltextzugriff (PDF)

511PMOLECULAR SUBGROUPS FROM THE AGITG MAX TRIAL; RIGHT OR LEFT PRIMARY SITE OF COLORECTAL CANCER AND OUTCOMES FOR METASTATIC COLORECTAL CANCER (MCRC)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv173-iv173

2014

Volltextzugriff (PDF)

741TiPRILOMET-1: AN INTERNATIONAL PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RILOTUMUMAB PLUS EPIRUBICIN, CISPLATIN AND CAPECITABINE (ECX) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED MET-POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (G/GEJ) ADENOCARCINOMA

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv250-iv250

2014

Volltextzugriff (PDF)

Molecular Subgroups from the Agitg Max Trial; Right or Left Primary Site of Colorectal Cancer and Outcomes for Metastatic Colorectal Cancer (Mcrc)

Annals of oncology, 2014-09, Vol.25, p.iv173

2014

Volltextzugriff (PDF)

Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer (MCRC): First-Line Analysis of Pooled Data From Randomized Controlled Trials (RCTS)

Annals of oncology, 2012-09, Vol.23, p.ix189

2012

Volltextzugriff (PDF)

555P - Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer (MCRC): First-Line Analysis of Pooled Data From Randomized Controlled Trials (RCTS)

Annals of oncology, 2012-09, Vol.23, p.ix189-ix189

2012

Volltextzugriff (PDF)

Systemic treatment of colorectal cancer

European journal of cancer (1990), 2002-05, Vol.38 (7), p.1000-1015

2002

Volltextzugriff (PDF)

519O - Final Results of Australasian Gastro-Intestinal Trials Group (AGITG) Arctic Study: AN International Audit of Raltitrexed for Patients with Cardiac Toxicity Induced by Fluoropyrimidines (FP)

Annals of oncology, 2012-09, Vol.23, p.ix178-ix178

2012

Volltextzugriff (PDF)

Final Results of Australasian Gastro-Intestinal Trials Group (AGITG) Arctic Study: AN International Audit of Raltitrexed for Patients with Cardiac Toxicity Induced by Fluoropyrimidines (FP)

Annals of oncology, 2012-09, Vol.23, p.ix178

2012

Volltextzugriff (PDF)

Preoperative Chemoradiotherapy and Postoperative Chemotherapy with Capecitabine +/- Oxaliplatin in Locally Advanced Rectal Cancer: Interim Analysis for Disease-Free Survival of Petacc 6

Annals of oncology, 2014-09, Vol.25, p.iv170

2014

Volltextzugriff (PDF)

721PA MULTI-CENTRE, PHASE II, OPEN-LABEL, SINGLE ARM STUDY OF PANITUMUMAB, CISPLATIN AND GEMCITABINE IN BILIARY TRACT CANCER: PRIMARY RESULTS OF THE AGITG TACTIC STUDY

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv244-iv244

2014

Volltextzugriff (PDF)

505PDPREOPERATIVE CHEMORADIOTHERAPY AND POSTOPERATIVE CHEMOTHERAPY WITH CAPECITABINE +/- OXALIPLATIN IN LOCALLY ADVANCED RECTAL CANCER: INTERIM ANALYSIS FOR DISEASE-FREE SURVIVAL OF PETACC 6

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv170-iv171

2014

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Humans
(12)
Aged
(11)
Female
(11)
Life Sciences & Biomedicine
(11)
Male
(11)
Science & Technology
(11)
Aged, 80 And Over
(10)
Middle Aged
(10)
Oncology
(10)
Adult
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Colorectal Neoplasms - Drug Therapy
(7)
Biological And Medical Sciences
(6)
Disease-Free Survival
(6)
Medical Sciences
(6)
Antineoplastic Agents
(5)
Chemotherapy
(5)
Colorectal Cancer
(5)
Colorectal Neoplasms - Pathology
(5)
Gastroenterology. Liver. Pancreas. Abdomen
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(24)
European Journal Of Cancer
(2)
Clinical Oncology
(1)
Gut
(1)
Leukemia & Lymphoma
(1)
Therapeutic Advances In Medical Oncology
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer

Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C

435P The AGITG Modulate study: Randomised phase II study testing manipulation of the tumour micro environment (TME) to enable synergy with PD1 inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

1670P Circulating tumor DNA (ctDNA) dynamics of response and resistance in BRAF V600E mutant (mt) metastatic colorectal (mCRC) and other cancers: Data from EVICT (erlotinib and vemurafenib in combination trial)

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases

Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer

Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17

Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer

Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Therapy in Patients with Advanced Met-Positive Gastric or Gastroesophageal Junction (G/Gej) Adenocarcinoma

511PMOLECULAR SUBGROUPS FROM THE AGITG MAX TRIAL; RIGHT OR LEFT PRIMARY SITE OF COLORECTAL CANCER AND OUTCOMES FOR METASTATIC COLORECTAL CANCER (MCRC)

741TiPRILOMET-1: AN INTERNATIONAL PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RILOTUMUMAB PLUS EPIRUBICIN, CISPLATIN AND CAPECITABINE (ECX) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED MET-POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (G/GEJ) ADENOCARCINOMA

Molecular Subgroups from the Agitg Max Trial; Right or Left Primary Site of Colorectal Cancer and Outcomes for Metastatic Colorectal Cancer (Mcrc)

Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer (MCRC): First-Line Analysis of Pooled Data From Randomized Controlled Trials (RCTS)

555P - Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer (MCRC): First-Line Analysis of Pooled Data From Randomized Controlled Trials (RCTS)

Systemic treatment of colorectal cancer

519O - Final Results of Australasian Gastro-Intestinal Trials Group (AGITG) Arctic Study: AN International Audit of Raltitrexed for Patients with Cardiac Toxicity Induced by Fluoropyrimidines (FP)

Final Results of Australasian Gastro-Intestinal Trials Group (AGITG) Arctic Study: AN International Audit of Raltitrexed for Patients with Cardiac Toxicity Induced by Fluoropyrimidines (FP)

Preoperative Chemoradiotherapy and Postoperative Chemotherapy with Capecitabine +/- Oxaliplatin in Locally Advanced Rectal Cancer: Interim Analysis for Disease-Free Survival of Petacc 6

721PA MULTI-CENTRE, PHASE II, OPEN-LABEL, SINGLE ARM STUDY OF PANITUMUMAB, CISPLATIN AND GEMCITABINE IN BILIARY TRACT CANCER: PRIMARY RESULTS OF THE AGITG TACTIC STUDY

505PDPREOPERATIVE CHEMORADIOTHERAPY AND POSTOPERATIVE CHEMOTHERAPY WITH CAPECITABINE +/- OXALIPLATIN IN LOCALLY ADVANCED RECTAL CANCER: INTERIM ANALYSIS FOR DISEASE-FREE SURVIVAL OF PETACC 6

Suchergebnisse filtern